Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2011

View Archived Issues

Roche discovers novel class of inhibitors of the hexosamine biosynthesis pathway

U.K. study describes distribution of transient receptor potential TRPA1 channel in human lung

Novel engineered physiocrine has thrombopoietic effects in vivo

Large-scale phase III trial assesses ChimeriVax-Dengue vaccine in Singapore

Valeant Pharmaceuticals reports phase III data on efinaconazole

Promising results emerge from first phase III tedizolid trial in ABSSSI

Antisense therapy enters phase I trial in children with spinal muscular atrophy

Ardea Biosciences initiates phase III lesinurad program

Trimel Pharmaceuticals announces completion of phase II TBS-2 trial in anorgasmia

Hanmi and Kinex sign Orascovery licensing agreement

Xarelto obtains E.U. approval in two new indications

Enrollment complete in first phase III migalastat hydrochloride trial

Lundbeck reports on MAA for Selincro

AbGenomics to regain rights to immunotherapeutic for psoriasis and other immunological diseases

NewGen Therapeutics acquires targeted oncology programs

Phase I trials evaluate candidate prime-boost malaria vaccine regimen in healthy adults and children

Canadian university prepares new prostanoid EP4 receptor agonists

Novel epidermal growth factor receptor inhibitors synthesized by Chinese university

New lysophospholipid S1P1 receptor ligands patented by the Institute of Materia Medica

Hande Starlake Bioscience prepares new PARP inhibitors

Boehringer Ingelheim discloses new chemokine CCR2 receptor antagonists

FDA approves fixed-dose combination tablet for treatment of hypertension

FDA accepts tofacitinib NDA for review

Orexo reports novel pharmacokinetic findings for breakthrough cancer pain treatment

BioDelivery Sciences reports on confirmatory BEMA-buprenorphine/naloxone trial

Novartis stops phase III aliskiren hemifumarate trial

Takeda to expand oncology pipeline with acquisition of Intellikine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...